BR112013015602B1 - Comprimido farmacêutico compreendendo solvato de dimetil sulfóxido de n-{3-[3- ciclopropil-5-(2-fluoro-4-iodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, e seu processo de preparação - Google Patents

Comprimido farmacêutico compreendendo solvato de dimetil sulfóxido de n-{3-[3- ciclopropil-5-(2-fluoro-4-iodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, e seu processo de preparação Download PDF

Info

Publication number
BR112013015602B1
BR112013015602B1 BR112013015602-3A BR112013015602A BR112013015602B1 BR 112013015602 B1 BR112013015602 B1 BR 112013015602B1 BR 112013015602 A BR112013015602 A BR 112013015602A BR 112013015602 B1 BR112013015602 B1 BR 112013015602B1
Authority
BR
Brazil
Prior art keywords
dimethyl
pharmaceutical tablet
tetrahydro
fluoro
phenyl
Prior art date
Application number
BR112013015602-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112013015602A2 (pt
Inventor
Douglas J. Demarini
Ngocdiep T. Le
Francisco Henriquez
Lihong Wang
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46314827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112013015602(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112013015602A2 publication Critical patent/BR112013015602A2/pt
Publication of BR112013015602B1 publication Critical patent/BR112013015602B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/06—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of pills, lozenges or dragees
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112013015602-3A 2010-12-20 2011-12-20 Comprimido farmacêutico compreendendo solvato de dimetil sulfóxido de n-{3-[3- ciclopropil-5-(2-fluoro-4-iodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, e seu processo de preparação BR112013015602B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201061424967P 2010-12-20 2010-12-20
US61/424,967 2010-12-20
PCT/US2011/066021 WO2012088033A2 (en) 2010-12-20 2011-12-20 Novel pharmaceutical composition

Publications (2)

Publication Number Publication Date
BR112013015602A2 BR112013015602A2 (pt) 2017-02-21
BR112013015602B1 true BR112013015602B1 (pt) 2022-03-03

Family

ID=46314827

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112013015602-3A BR112013015602B1 (pt) 2010-12-20 2011-12-20 Comprimido farmacêutico compreendendo solvato de dimetil sulfóxido de n-{3-[3- ciclopropil-5-(2-fluoro-4-iodo-fenilamino)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2h-pirido[4,3-d]pirimidin-1-il]fenil}acetamida, e seu processo de preparação

Country Status (38)

Country Link
US (5) US20130266649A1 (https=)
EP (4) EP2654736B1 (https=)
JP (2) JP6126014B2 (https=)
KR (1) KR101911109B1 (https=)
CN (1) CN103998041B (https=)
AR (2) AR084102A1 (https=)
AU (1) AU2011349422B2 (https=)
BR (1) BR112013015602B1 (https=)
CA (1) CA2822701C (https=)
CL (1) CL2013001779A1 (https=)
CR (1) CR20130352A (https=)
CY (1) CY1123376T1 (https=)
DK (3) DK4159205T3 (https=)
DO (1) DOP2013000138A (https=)
EA (1) EA025198B1 (https=)
ES (3) ES2985024T3 (https=)
FI (2) FI4159204T3 (https=)
HR (3) HRP20201409T1 (https=)
HU (3) HUE050788T2 (https=)
IL (1) IL226855A (https=)
JO (1) JO3594B1 (https=)
LT (3) LT4159205T (https=)
MA (1) MA34883B1 (https=)
MX (1) MX2013007073A (https=)
MY (1) MY170501A (https=)
NZ (1) NZ612157A (https=)
PE (1) PE20140040A1 (https=)
PH (1) PH12013501209A1 (https=)
PL (3) PL4159205T3 (https=)
PT (3) PT2654736T (https=)
RS (2) RS65497B1 (https=)
SG (1) SG191054A1 (https=)
SI (3) SI2654736T1 (https=)
TW (1) TWI505828B (https=)
UA (1) UA113158C2 (https=)
UY (1) UY33818A (https=)
WO (1) WO2012088033A2 (https=)
ZA (1) ZA201304189B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
DK2884979T3 (da) 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
AU2013352369B2 (en) * 2012-11-30 2016-07-28 Novartis Ag. Novel pharmaceutical composition
WO2015019125A1 (en) * 2013-08-05 2015-02-12 Societe De Developpement Et De Recherche Industrielle Molecular targets for the treatment of wounds, in particular chronic wounds
CN103819471A (zh) * 2013-11-25 2014-05-28 镇江圣安医药有限公司 吡啶并(4,3-d)嘧啶-1（2H）-基苯基乙酰胺的衍生物及其应用
CN104918937B (zh) * 2013-12-06 2016-09-14 杭州普晒医药科技有限公司 曲美替尼及其溶剂化物的晶型、其制备方法、含有它们的药物组合物及其用途
EP2913048A1 (en) * 2014-02-27 2015-09-02 ratiopharm GmbH Pharmaceutical composition comprising trametinib
WO2016126012A1 (en) * 2015-02-05 2016-08-11 Boryung Pharmaceutical Co., Ltd Tablet and method of preparing the same
KR101545268B1 (ko) 2015-02-05 2015-08-20 보령제약 주식회사 정제 및 이의 제조방법
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US20170020880A1 (en) * 2015-07-22 2017-01-26 Hetero Research Foundation Pharmaceutical compositions of trametinib
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
RU2627692C1 (ru) * 2016-10-10 2017-08-10 Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") N-{ 3-[3-циклопропил-5-(2-фторо-4-иодофениламино)-6,8-диметил-2,4,7-триоксо-3,4,6,7-тетрагидро-2Н-пиридо[4,3-d]пиримидин-1-ил]-фенил} -циклопропанкарбоксамида диметилсульфоксида сольват в качестве ингибитора МЕК1/2
JP2019535696A (ja) * 2016-11-25 2019-12-12 ジエンス ヘンルイ メデイシンカンパニー リミテッドＪｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．，Ｌｔｄ． ピリドン誘導体の医薬組成物およびその製造方法
ES2952265T3 (es) 2017-05-02 2023-10-30 Novartis Ag Terapia combinada que comprende un inhibidor de Raf y trametinib
ES3025633T3 (en) 2019-05-13 2025-06-09 Novartis Ag New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
CN114340670B (zh) 2019-07-11 2026-02-17 普拉克西斯精密药物股份有限公司 T-型钙通道调节剂的制剂及其使用方法
EP4725489A2 (en) 2019-08-02 2026-04-15 OneHealthCompany, Inc. Treatment of canine cancers
RU2749719C1 (ru) * 2020-10-08 2021-06-16 Нестерук Владимир Викторович Препарат для лечения анемии, связанной с хроническим заболеванием почек, и способ его получения
US20250032494A1 (en) 2021-12-06 2025-01-30 My Personal Therapeutics Ltd A combination treatment for cancer
WO2024171019A1 (en) * 2023-02-13 2024-08-22 Alembic Pharmaceuticals Limited Pharmaceutical composition of trametinib and process of preparation thereof
WO2025132408A2 (en) 2023-12-21 2025-06-26 Synthon B.V. Solvates of trametinib

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727077A (en) 1985-02-20 1988-02-23 Ishihara Sangyo Kaisha Ltd. Benzoyl urea compounds, process for their production, and antitumorous compositions containing them
JPS61205257A (ja) * 1985-03-08 1986-09-11 Ishihara Sangyo Kaisha Ltd ベンゾイルウレア系化合物、その製法及びそれを含有する抗ガン剤
US5559235A (en) 1991-10-29 1996-09-24 Glaxo Wellcome Inc. Water soluble camptothecin derivatives
US5342947A (en) 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US5491237A (en) 1994-05-03 1996-02-13 Glaxo Wellcome Inc. Intermediates in pharmaceutical camptothecin preparation
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6825180B2 (en) 2001-05-18 2004-11-30 Cell Therapeutics, Inc. Pyridopyrimidine compounds and their uses
US7378423B2 (en) 2004-06-11 2008-05-27 Japan Tobacco Inc. Pyrimidine compound and medical use thereof
AU2005252110B2 (en) * 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
US7955622B2 (en) * 2006-10-13 2011-06-07 Actavis Group Ptc Hf Controlled-release galantamine formulations
CA2668724A1 (en) * 2006-11-09 2008-05-22 Gilead Colorado, Inc. Darusentan oral dosage form
JO2985B1 (ar) * 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
UA99731C2 (ru) * 2007-07-30 2012-09-25 Ардеа Биосайенсис, Инк Кристаллические полиморфные формы n-(ариламино)сульфонамидов как ингибиторы мэк, композиция (варианты) и применение
BRPI0817946A2 (pt) * 2007-09-25 2015-05-05 Teva Pharma Composições de imatinibe estável
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
EP2392576B1 (en) * 2008-07-08 2016-02-17 Beta Pharma, Inc. Icotinib hydrochloride, synthesis, crystallographic form, medical combination, and uses thereof
CN102762098B (zh) 2009-09-23 2015-10-14 葛兰素史密斯克莱有限责任公司 组合
AU2010298277B2 (en) 2009-09-23 2014-07-03 Novartis Ag Combination
MX2012003779A (es) * 2009-09-28 2012-06-01 Glaxosmithkline Llc Combinacion.
US8703781B2 (en) * 2009-10-16 2014-04-22 Glaxosmithkline Llc Pharmaceutical combination of MEK inhibitor and B-RAF inhibitors
MX2012005758A (es) 2009-11-17 2012-06-19 Glaxosmithkline Llc Combinacion.
EP2608790A4 (en) 2010-08-26 2014-04-02 Glaxosmithkline Llc PHARMACEUTICAL COMBINATION OF A VEGFR-INHIBITOR AND A MEK-INHIBITOR FOR THE TREATMENT OF CANCER
TWI505828B (zh) 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
US8977217B1 (en) 2013-02-20 2015-03-10 Triquint Semiconductor, Inc. Switching device with negative bias circuit
CZ2015278A3 (cs) 2015-04-24 2016-11-02 Zentiva, K.S. Krystalické formy trametinibu

Also Published As

Publication number Publication date
DK4159204T3 (da) 2024-05-21
EP2654736B1 (en) 2020-07-01
CA2822701C (en) 2018-10-23
EP3808343A1 (en) 2021-04-21
CN103998041A (zh) 2014-08-20
FI4159205T3 (fi) 2024-04-23
ES2982775T3 (es) 2024-10-17
PT4159205T (pt) 2024-05-08
HRP20201409T1 (hr) 2020-11-27
ES2820536T3 (es) 2021-04-21
JP2014510704A (ja) 2014-05-01
US20140154316A1 (en) 2014-06-05
CL2013001779A1 (es) 2014-06-27
AR084102A1 (es) 2013-04-24
TW201249441A (en) 2012-12-16
LT4159205T (lt) 2024-05-10
SG191054A1 (en) 2013-08-30
MY170501A (en) 2019-08-08
EP4159204A1 (en) 2023-04-05
TWI505828B (zh) 2015-11-01
HUE066526T2 (hu) 2024-08-28
EP2654736A4 (en) 2015-04-22
US20140037726A1 (en) 2014-02-06
PT4159204T (pt) 2024-05-07
US20120183613A1 (en) 2012-07-19
SI4159204T1 (sl) 2024-06-28
ES2985024T3 (es) 2024-11-04
NZ612157A (en) 2015-05-29
CR20130352A (es) 2013-12-18
UY33818A (es) 2012-07-31
RS65496B1 (sr) 2024-06-28
US20140099365A1 (en) 2014-04-10
ZA201304189B (en) 2014-02-26
JP6126014B2 (ja) 2017-05-10
US9271941B2 (en) 2016-03-01
HUE066525T2 (hu) 2024-08-28
SI4159205T1 (sl) 2024-06-28
MA34883B1 (fr) 2014-02-01
FI4159204T3 (fi) 2024-04-22
PL4159205T3 (pl) 2024-06-24
AR122185A2 (es) 2022-08-24
HUE050788T2 (hu) 2021-01-28
EP4159204B1 (en) 2024-02-14
PL4159204T3 (pl) 2024-07-01
US9399021B2 (en) 2016-07-26
PE20140040A1 (es) 2014-02-26
PT2654736T (pt) 2020-09-24
US8580304B2 (en) 2013-11-12
AU2011349422B2 (en) 2015-12-10
JO3594B1 (ar) 2020-07-05
PL2654736T3 (pl) 2020-12-14
DK4159205T3 (da) 2024-05-13
KR20130130028A (ko) 2013-11-29
SI2654736T1 (sl) 2020-10-30
US9155706B2 (en) 2015-10-13
EP4159205B1 (en) 2024-02-14
LT4159204T (lt) 2024-05-10
EA201390913A1 (ru) 2014-04-30
RS65497B1 (sr) 2024-06-28
EP2654736A2 (en) 2013-10-30
UA113158C2 (xx) 2016-12-26
CY1123376T1 (el) 2021-12-31
WO2012088033A3 (en) 2014-03-13
HRP20240563T1 (hr) 2024-08-16
AU2011349422A1 (en) 2013-05-02
CN103998041B (zh) 2016-08-17
JP2017137299A (ja) 2017-08-10
CA2822701A1 (en) 2012-06-28
DOP2013000138A (es) 2013-11-30
US20130266649A1 (en) 2013-10-10
LT2654736T (lt) 2020-09-25
WO2012088033A2 (en) 2012-06-28
BR112013015602A2 (pt) 2017-02-21
KR101911109B1 (ko) 2018-10-23
DK2654736T3 (da) 2020-09-14
MX2013007073A (es) 2013-09-26
EP4159205A1 (en) 2023-04-05
IL226855A (en) 2017-04-30
HRP20240564T1 (hr) 2024-09-27
PH12013501209A1 (en) 2013-07-29
EA025198B1 (ru) 2016-11-30

Similar Documents

Publication Publication Date Title
JP6126014B2 (ja) 新規医薬組成物
AU2013352369B2 (en) Novel pharmaceutical composition
HK40086707A (en) Novel pharmaceutical composition
HK40086707B (en) Novel pharmaceutical composition
HK40086699B (en) Novel pharmaceutical composition
HK40086699A (en) Novel pharmaceutical composition
HK40043030A (en) Novel pharmaceutical composition
US20150306099A1 (en) Combination
AU2014206138A1 (en) Combination

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25C Requirement related to requested transfer of rights

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMIT

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT

B25A Requested transfer of rights approved

Owner name: NOVARTIS PHARMA AG (CH)

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 20/12/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.